Preliminary data from our group, showing the safety of BCG vaccination in VIS, encouraged studies to assess the efficacy of -his approach. A single crossover, magnetic resonance (MR)-monitored trial was undertaken in 11 relapsing-remitting patients with definite MS (disease duration <6 years; EDSS <3,5). Patients have been 'ollowed-up monthly with gadolinium-enhanced MR scans for 6 nonths of run-in and, similarly, for 6 months after one single intracutaneous dose of 0.1 ml freeze-dried BCG vaccine (1 mg;ml) (Berna Institute, Basel). A preliminary Mantoux reaction was performed to exclude hyperergic patients. Seven patients received BCG so far and 3 of them have completed the study. During the run-in period, 13 active scans (oui of a total of 42) and 5 relapses (3 of them treated with Tiethylprednisolone. Igr. i.v. daily for five days) were observed. .Vfter treatment, the 7 vaccinated patients presented 3 active scans out of the 33 recorded so far, while neither relapses nor idverse effects were observed. These data confirm the safety of this approach and suggest its possible efficacy in MS. Data on Uie complete follow-up of patients will be available by September 1997
Bacille calmette guerin (BCG) vacclne in vfultiple sclerosis (MS): A single cross-over study
Sabatini U;
1997-01-01
Abstract
Preliminary data from our group, showing the safety of BCG vaccination in VIS, encouraged studies to assess the efficacy of -his approach. A single crossover, magnetic resonance (MR)-monitored trial was undertaken in 11 relapsing-remitting patients with definite MS (disease duration <6 years; EDSS <3,5). Patients have been 'ollowed-up monthly with gadolinium-enhanced MR scans for 6 nonths of run-in and, similarly, for 6 months after one single intracutaneous dose of 0.1 ml freeze-dried BCG vaccine (1 mg;ml) (Berna Institute, Basel). A preliminary Mantoux reaction was performed to exclude hyperergic patients. Seven patients received BCG so far and 3 of them have completed the study. During the run-in period, 13 active scans (oui of a total of 42) and 5 relapses (3 of them treated with Tiethylprednisolone. Igr. i.v. daily for five days) were observed. .Vfter treatment, the 7 vaccinated patients presented 3 active scans out of the 33 recorded so far, while neither relapses nor idverse effects were observed. These data confirm the safety of this approach and suggest its possible efficacy in MS. Data on Uie complete follow-up of patients will be available by September 1997I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
